Image

GRAvity- Versus Wall Suction-drIven Large Volume Thoracentesis: a rAndomized Controlled Study (GRAWITAS Study)

GRAvity- Versus Wall Suction-drIven Large Volume Thoracentesis: a rAndomized Controlled Study (GRAWITAS Study)

Non Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

The primary objective of this study is to compare gravity-driven versus wall suction-driven large volume therapeutic thoracentesis on the development of chest discomfort during the procedure.

This study is a multicenter, single-blinded, randomized controlled trial designed to compare chest discomfort between gravity-driven and wall suction-driven therapeutic thoracentesis. Patients will be stratified by study centers, and randomly assigned to intervention and control arms; and will remain blinding to their group assignment during the procedure.

Description

Aims and Objectives:

The primary objective of this study is to compare gravity-driven versus wall suction-driven large volume therapeutic thoracentesis on the development of chest discomfort during the procedure.

Expected Outcomes:

We anticipate that gravity driven therapeutic thoracentesis will result in improved clinical outcomes compared to wall suction driven thoracentesis, defined by less chest discomfort throughout the procedure as measured at 5 minutes post-procedure (primary endpoint).

Primary endpoint:

The Global Pain Score will be determined at 5 minutes post-procedure using a VAS 0-100 and represents the pain experienced by the patient during the entire procedure from the beginning to the 5-minute post-procedure assessment ("On average, how much discomfort have you felt during the procedure?"). The primary endpoint is defined as the overall procedural chest pain scored 5 minutes following the procedure.

This study is a randomized controlled trial designed to compare the changes of chest pain scores between gravity-driven therapeutic thoracentesis and wall suction-driven thoracentesis. The estimated minimal clinically important difference of the change is 10.

Secondary endpoints:

  1. Duration of procedure timed from the beginning of fluid drainage to catheter removal.
  2. Differences in narcotics used after the procedure.
  3. Incidence of pneumothorax detected on the post procedural CXR
  4. Incidence of clinically apparent re-expansion pulmonary edema
  5. Incidence of radiographically apparent re-expansion pulmonary edema detected on the post procedural CXR

Eligibility

Inclusion criteria:

  1. Referral to pulmonary services for large-volume thoracentesis
  2. Presence of a symptomatic moderate or large free-flowing (non-septated) pleural effusion on the basis of:
    1. Chest radiograph: effusion filling ≥ 1/3 the hemithorax, OR
    2. CT-scan: maximum AP depth of the effusion ≥ 1/3 of the AP dimension on the axial image superior to the hemidiaphragm, including atelectatic lung completely surrounded by effusion, OR Ultrasound: effusion spanning at least three interspaces, with depth of 3 cm or greater in at least one intercostal space, while the patient sits upright.
  3. Age >/= 18

Exclusion criteria:

  1. Inability to provide informed consent
  2. Study subject has any disease or condition that interferes with safe completion of the study including:
    1. Coagulopathy, with criteria left at the discretion of the operator
    2. Hemodynamic instability with systolic blood pressure <90 mmHg or heart rate > 120 beats/min, unless deemed to be stable with these values by the attending physicians
  3. Pleural effusion is smaller than expected on bedside pre-procedure ultrasound
  4. Referral is for diagnostic thoracentesis only
  5. Presence of more than minimal septations and/or loculations( more than 3) on bedside pre-procedure ultrasound
  6. Inability to sit for the procedure
  7. Pregnancy

Study details
    Thoracentesis
    Pleural Effusions
    Chronic
    Pulmonary Edema

NCT05131945

M.D. Anderson Cancer Center

20 August 2025

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.